Krushna C. Patra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Krushna C. Patra has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Maria F. Czyzyk-Krzeska
Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
45 shared publications - Amelia Martines
Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio
44 shared publications - Angelo D'Alessandro
University of Colorado Anschutz Medical Campus
44 shared publications - Behrouz Shamsaei
University of Cincinnati, College of Medicine
44 shared publications - Bhargav Vemuri
Phenome Health, Seattle, WA, 98121, USA
44 shared publications - Caterina Bartolacci
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
44 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (40)
Remodeling of mitochondrial dynamics by metabolic pathways couples to oncogenic growth in GNAS (Gα s ) mutant pancreas cancer
Maintenance of fissed mitochondria is viewed as a defining feature of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant cancers. However, regulation of this process by accompanying comutations or environmental factors is not clearly defined. Here, by analyzing a subset of pancreatic cancer lesions driven by concurrent Kras G12D and GNAS complex locus gene (GNAS R201C/H ) mutations, we found that despite the presence of mutant Kras, hyperactive Gnas R201C maintains mitochondria predominantly in a fused state, which is necessary for tumor growth. Multiplex proteomics, super-resolution microscopy, loss- and gain-of-function studies, coupled with metabolite rescue experiments, revealed that Gnas R201C -regulated branched-chain amino acid (BCAA) pathway is a previously unidentified regulator of mitochondrial morphology. Mechanistically, the BCAA pathway, the associated tricarboxylic acid cycle, and aspartate metabolism converge on nicotinamide adenine dinucleotide (NADH-NAD + ) metabolites to promote mitochondrial elongation. NAD + availability is crucial for mitochondrial fusion, as facilitating NAD + generation through alternative means promotes fusion. Collectively, we unraveled a new mechanism that drives mitochondrial fusion and showed that the combination of oncogenic signaling and metabolism can maintain distinct mitochondrial morphology within genetic subsets of KRAS-mutant pancreatic cancer.
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (40)
Open AccessRemodeling of mitochondrial dynamics by metabolic pathways couples to oncogenic growth in GNAS (Gα s ) mutant pancreas cancer
Maintenance of fissed mitochondria is viewed as a defining feature of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant cancers. However, regulation of this process by accompanying comutations or environmental factors is not clearly defined. Here, by analyzing a subset of pancreatic cancer lesions driven by concurrent Kras G12D and GNAS complex locus gene (GNAS R201C/H ) mutations, we found that despite the presence of mutant Kras, hyperactive Gnas R201C maintains mitochondria predominantly in a fused state, which is necessary for tumor growth. Multiplex proteomics, super-resolution microscopy, loss- and gain-of-function studies, coupled with metabolite rescue experiments, revealed that Gnas R201C -regulated branched-chain amino acid (BCAA) pathway is a previously unidentified regulator of mitochondrial morphology. Mechanistically, the BCAA pathway, the associated tricarboxylic acid cycle, and aspartate metabolism converge on nicotinamide adenine dinucleotide (NADH-NAD + ) metabolites to promote mitochondrial elongation. NAD + availability is crucial for mitochondrial fusion, as facilitating NAD + generation through alternative means promotes fusion. Collectively, we unraveled a new mechanism that drives mitochondrial fusion and showed that the combination of oncogenic signaling and metabolism can maintain distinct mitochondrial morphology within genetic subsets of KRAS-mutant pancreatic cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Bulk RNA and spatial transcriptomics analysis of ccRCC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Bulk RNA and spatial transcriptomics analysis of ccRCC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Accumulation of Cu and its allocation to CuCOX correlates with the progression of ccRCC and drives tumor growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Accumulation of Cu and its allocation to CuCOX correlates with the progression of ccRCC and drives tumor growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Contents of Supplementary Tables from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
List of contents of each Supplementary Table
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessContents of Supplementary Tables from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
List of contents of each Supplementary Table
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S7 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S7 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Steady-state metabolomics in CuHi and CuLo cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Steady-state metabolomics in CuHi and CuLo cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Differential gene expression in tumors from S3DF and S3RL patients.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Differential gene expression in tumors from S3DF and S3RL patients.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Cu induces NRF2-dependent activation of glutathione biosynthesis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Cu induces NRF2-dependent activation of glutathione biosynthesis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Differential gene expression in CuHi and CuLo 786-O cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Differential gene expression in CuHi and CuLo 786-O cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Gene signatures in scRNA-seq analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma
Gene signatures in scRNA-seq analysis